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Background: Silent brain infarcts are common in patients at increased risk of stroke and 
are associated with a poor prognosis. In patients with asymptomatic carotid stenosis similar 
adverse associations were claimed, but the impact of previous infarction or symptoms on 
the beneficial effects of carotid endarterectomy (CEA) is not clear. Our aim was to evaluate 
the impact of prior cerebral infarction in patients enrolled in the Asymptomatic Carotid 
Surgery Trial (ACST-1), a large trial with 10-year follow-up in which participants whose 
carotid stenosis had not caused symptoms for at least 6 months were randomly allocated 
either immediate or deferred CEA. 
Methods:  ACST-1 included 3120 patients. Of these, 2333 patients with baseline brain 
imaging were identified and divided into 2 groups irrespective of treatment assignment, 
1331 with evidence of previous cerebral infarction, defined as a history of ischaemic stroke 
or TIA >6 months prior to randomization or radiological evidence of an asymptomatic infarct 
(Group 1) and 1002 with normal imaging and no prior stroke or TIA (Group 2). Stroke and 
vascular death were compared during follow-up and the impact of CEA was observed in 
both groups.  
Results: Baseline characteristics of patients with and without baseline brain imaging were 
broadly similar. Of those included in the present report, male gender and hypertension were 
more common in Group 1 while mean ipsilateral stenosis was slightly greater in Group 2. At 
10 years follow-up, stroke was more common among participants with cerebral infarction 
before randomization (absolute risk increase [ARI] 5.8% [1.8-9.8], p=0.004) and risk of 
stroke and vascular death was also higher in this group (ARI 6.9% [1.9-12.0], p=0.007). On 
multivariate analysis, prior cerebral infarction was associated with a greater risk of stroke 





(HR=1.51 95%CI: 1.17-1.95, p=0.002) and of stroke or other vascular death (HR=1.30 
95%CI: 1.11-1.52, p=0.001).  
At 10 years, greater absolute benefits from immediate CEA were seen in those patients 
with prior cerebral infarction (6.7% strokes immediate CEA vs. 14.7% delayed CEA; HR 
0.47 [0.34-0.65]; p=0.003), compared to those lower risk patients without prior cerebral 
infarction (6.0% vs. 9.9% respectively; HR 0.61 [0.39-0.94]; p=0.005), though it must be 
emphasized that ACST-1 was not designed to test this retrospective and non-randomized 
comparison. 
Conclusions: Asymptomatic carotid stenosis patients with prior cerebral infarction have a 
higher stroke risk during long-term follow-up than those without prior cerebral infarction. 
Evidence of prior ischemic events might help identify patients in whom carotid intervention 










The term “silent brain infarcts” is widely used to describe brain infarcts seen on brain 
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) without any 
corresponding clinical symptoms. These lesions are common, especially on brain MRI, 
ranging from 20% in the general elderly population to up to 50% in patients at high risk of 
stroke.(1) Silent cerebral infarction is associated with poor outcome in most studies, with 
around a two-fold increase in the risk of stroke.(1) Earlier studies reported 23% patients 
with asymptomatic significant carotid stenosis had silent cerebral infarction on brain MRI (2) 
(and 15-18% on CT scans) (3,4) but the importance of such lesions was unclear.(4,5) 
Whilst one study (5) concluded that carotid endarterectomy (CEA) for asymptomatic 
stenosis patients with silent cerebral infarction might not be justified, a later one (4) 
suggested that silent cerebral infarction ipsilateral to an asymptomatic stenosis could help 
identify a high stroke-risk group and might prove useful in selecting appropriate patients for 
CEA. In the NASCET trial the presence of ipsilateral cerebral infarction on CT in patients 
presenting with transient ischemic attacks (TIA's) did not affect their prognosis, (6) but, in 
another, more recent study, brain lesions (mainly on MRI's) were found to be important in 
identifying TIA patients at higher stroke risk. (7)   
The aim of our study was to investigate, in a large group of asymptomatic carotid stenosis 
patients with long-term follow-up drawn from the Asymptomatic Carotid Surgery Trial-1 
(ACST-1), whether cerebral infarction at admission to the study was associated with poorer 
outcomes compared with patients with normal brain imaging. ACST-1, with large numbers 
of patients and 10-year follow-up allows uniquely reliable assessment of this outcome. 





Materials and methods 
Details of the ACST-1 trial have been published previously.(8, 9) Between 1993 and 2003, 
3120 patients with high grade unilateral or bilateral asymptomatic carotid artery stenosis  
whose carotid stenosis has not caused symptoms for at least 6 months and who had no 
past history of ipsilateral disabling or severe contralateral stroke were randomly allocated to 
either immediate CEA or deferral of surgery until it appeared to be more clearly indicated. 
The aim of the trial was to determine whether immediate CEA and best current medical 
treatment improved stroke free survival when compared with best medical treatment alone 
(deferred CEA being undertaken as needed). 
Patients’ comorbidities (including hypertension, diabetes, and coronary artery disease) and 
concurrent medications (including antiplatelet therapy, anticoagulants and statin use) were 
recorded prospectively. Carotid artery stenosis was measured by Doppler ultrasound and 
recorded as percentage luminal diameter reduction, usually rounded to the nearest decile.  
Whilst some form of baseline brain imaging (CT or MRI) was often undertaken, it was not a 
requirement for randomization, and around one quarter of trial participants had no pre- 
randomization scans. For those patients who had brain scans, presence or absence of 
ipsilateral, contralateral, bilateral or vertebrobasilar infarcts was recorded by the investigator 
at baseline. During follow-up, information regarding any CEA, perioperative morbidity, 
stroke, death, blood pressure, and current drug treatment was recorded. Annual carotid 
ultrasound was requested for the first 5 years after randomization.  
Primary trial outcomes were perioperative mortality and morbidity (death or stroke within 30 
days of CEA) and non-peri-operative stroke. Events were adjudicated centrally by members 
of the endpoint review committee, who were blinded to treatment allocation. Strokes were 
classified according to location (ipsilateral, contralateral, vertebrobasilar), cause 





(haemorrhagic, probably cardioembolic, other ischaemic [lacunar]) and outcome after 6 
months (ie, non-disabling, disabling, fatal). Most analyses were of first strokes; analyses of 
further worst strokes counted patients only once, and fatal strokes were those that caused 
death directly or indirectly.(8, 9) 
 
Design of this study 
Previous cerebral infarction was defined as a history of ischaemic stroke or TIA in any 
territory occurring >6 months prior to randomization or radiological evidence of an 
asymptomatic, or ‘silent’ brain infarct. Patients fitting this definition were included in Group 1 
(relevant symptoms reported at baseline are shown in Table 1), and those without previous 
cerebral infarction were included in Group 2. Patients with prior stroke or TIA were included 
in Group 1 even if their imaging was reported as normal. We excluded patients with no 
imaging before inclusion who were free of previous events. 
 
Statistical analysis  
Using minimised randomisation patients were allocated to immediate CEA or deferral of any 
carotid surgery. Analyses of the effects of immediate versus deferred carotid surgery in 
both groups were by original treatment allocation (ie, intention-to-treat).  Baseline 
differences between the two groups were examined with Pearson Chi-square test for 
binominal variables, and Student's t-test for continuous variables.  A Cox proportional 
hazard model was calculated to assess the independent association between type of stroke 
or cause of death for the two groups thereby correcting for baseline differences and 
potential confounders. 





Differences in clinical outcome (stroke, and a composite outcome of any stroke or vascular 
death) between the two groups were assessed with Cox regression survival analyses and 
separated by baseline characteristics. 
Results 
Of the 3120 participants, 787 patients had no imaging at study entry and were excluded. 
Their characteristics were quite similar to the included patients (Table S1) apart from higher 
rates of known cardiac diseases and of significant contralateral stenosis. Ipsilateral stenosis 
was somewhat more severe in the analyzed group (only in categorical, not linear analysis) 
as was male gender. As previously described, pre-randomization brain imaging was left to 
the clinicians’ discretion, and rates of such imaging ranged from almost 90% in countries 
such as Italy, Israel, Germany and former Yugoslavia to about 20% in some UK and 
Swedish centers. 
Of the 2333 patients included in the present report, 1331 had previous cerebral infarction 
(Group 1) and 1002 had no infarction (Group 2). Only 30 patients were included in Group 1 
because of previous symptoms yet normal brain imaging. Patients' characteristics are 
shown in Table 2. There were more men in Group 1 but most risk factors were equally 
distributed (apart from hypertension which was commoner in Group 1). Severity of carotid 
stenosis was somewhat greater in those without brain lesions. Allocation to immediate CEA 
was around 50% in both groups (Table 2).  
Stroke outcome events and death outcome events are shown in Table 3 and Table S2 
respectively. As expected in patients with carotid disease, most strokes were ischaemic, 
arterial in origin and affected the carotid territory. About two thirds of carotid territory strokes 
in both groups were ipsilateral to the randomised artery. There were more carotid and 
vertebrobasilar territory strokes in Group 1, whilst the rates of hemorrhagic, lacunar and 





cardio-embolic strokes were lower in both groups. Disabling strokes were twice as common 
in Group 1. 
Stroke risk analysis is shown in Figure 1. At 10 years, stroke risk in Group 1 was 
significantly higher than in Group 2 (absolute risk increase [ARI] of 5.8% (95% CI 1.8-9.8), 
relative risk increase [RRI] 51% [fully adjusted hazard ratio HR=1.51 (95%CI 1.17-1.95), 
p=0.002]). 
About 40% of patients in both groups died within 10 years (Table S2). Prior cerebral 
infarction were associated with an increased risk of fatal stroke (61 [4.6%] in group 1 vs 29 
[2.9%] in group 2; p=0.009) and of strokes or vascular death (ARI 6.9% (1.9-12.0), p=0.007, 
RRI 30% [HR= 1.30 (95%CI 1.11-1.52), p=0.0009]) (Figure 2). 
In Table 4 (hazard ratio of stroke by patients' characteristics and risk factors) early CEA 
reduced stroke risk in both uni- and multivariable analyses, increasing age and presence of 
diabetes were independent risk factors for stroke, and prior cerebral infarction was a strong 
predictor of future stroke in the multivariable analyses. In Table S3 (analysis of stroke and 
vascular death by risk factors), male gender and presence of cardiac disease as well as the 
presence of prior cerebral infarction were important.  
When comparing effects of CEA in stroke prevention for each group, benefit of surgery was 
clear for both groups within 5 years, with greater absolute benefits of immediate CEA seen 
in those patients with prior brain infarcts. In this group, there were 45/676 (6.7%) strokes in 
the immediate group vs. 96/653 (14.7%) in the delayed group; HR 0.47 (0.34-0.65); 
p=0.003, compared to those lower risk patients without prior brain infarcts (29/484 [6.0%] 
vs. 51/516 [9.9%] respectively; HR 0.61 [0.39-0.94]; p=0.005). This greater absolute benefit 
was chiefly due to the higher underlying risk of stroke in the prior cerebral infarction group 
(5-year gain 4.9%, p=0.005% vs. 3.9%, p=0.02%), but also the larger relative risk reduction 
in stroke risk associated with allocation to immediate CEA observed in those with prior 





cerebral infarction. It should be emphasized that ACST-1 was not originally designed to test 
this retrospective and non-randomized comparison.  
 
Discussion 
These findings, in a large trial of patients with currently asymptomatic carotid stenosis, have 
shown that, although presently without symptoms, the finding of prior cerebral infarction 
(the vast majority of which were clinically silent), was associated with a significant increase 
in stroke risk and in deaths from stroke and vascular disease.  
In an older study (5), between 1986-1995, 301 asymptomatic carotid stenosis patients had 
CEA; prior to their surgery 34% of these patients had silent cerebral infarction. They were 
followed for a mean of just over 5 years and no significant difference was observed 
between the group with silent cerebral infarction and those without, either in perioperative 
morbidity, or in long-term mortality (22% vs. 15% p=0.1). Late strokes were more common 
in silent cerebral infarction patients (11% vs. 3%, p=0.006) and both lacunar and non-
lacunar infarcts were independent predictors of such events. The authors concluded that 
because silent cerebral infarction predicted poor stroke outcome (mostly unrelated to the 
diseased artery), a less aggressive attitude toward CEA in such patients might be justified. 
However, the present report shows that most strokes in patients with prior cerebral 
infarction were ischaemic, of arterial origin and in the carotid territory (two-thirds ipsilateral), 
suggesting that atherothrombosis of the carotid artery is a major source of continued stroke 
risk that could be significantly reduced by early intervention. Within 5 years, patients both 
with and without prior cerebral infarction benefitted from immediate CEA, but the former 
received greater absolute benefits. 
Results from the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) study,(4) 
which began at the same time as ACST-1, are consistent with our findings (5): ACSRS 





studied the natural history of asymptomatic carotid stenosis and followed 821 patients, who 
were not intended to have an operation, for a mean of 44.6 months. The investigators were 
principally interested in endpoints ipsilateral to the stenosed artery and in new silent 
cerebral infarction, considered to be embolic, which were identified ipsilateral to the side of 
the stenosis in 17.8% of the patients. At the end of follow-up the annual ipsilateral stroke 
rate was 4.6% in those with silent cerebral infarction, compared with 2.4% (p= 0.032) and 
this difference was more pronounced in patients with tighter stenoses (over 60%), including 
those with 60-79% stenosis. The authors concluded that patients with silent cerebral 
infarction were at increased risk of stroke and more likely to benefit from surgical 
intervention.(4) A recent review of the significance of silent cerebral infarction in 
asymptomatic carotid stenosis patients focused mainly on underlying aetiologies and likely 
mechanisms responsible for silent cerebral infarction(10). The authors concluded that 
micro-embolic signals (detected by transcranial Doppler) were the most important factor 
determining future stroke risk and that only silent cerebral infarction (cortical or subcortical) 
in the ICA territory was of prognostic significance. 
Our study is the largest study to prospectively assess the importance of prior cerebral 
infarction in patients with currently asymptomatic carotid artery stenosis, and has uniquely 
long follow-up. We have also shown that, whilst CEA reduces future stroke risks in such 
patients, prior brain infarction, especially in unoperated asymptomatic carotid stenosis 
patients, is an independent risk factor for future stroke and vascular death. 
Our study has some limitations: a significant number of patients did not have CT scan prior 
to randomization; their baseline characteristics, however, were broadly similar, and the 
presence or lack of baseline imaging was largely determined by centre location rather than 
individual participants’ features. The “best medical therapy” used during the trial study 





period has previously been discussed (8,9). Use of statins (and other cardio-vascular 
protective medications) significantly increased throughout the later years of the study; whilst 
we have shown that use of statins reduced overall stroke risk, the additional benefit of 
surgery (ARR 7%) was unaffected by statin use and persisted out to 10 years. [9] More 
recent observational studies of patients with high grade asymptomatic carotid stenosis are 
too small to provide reliable evidence on the effect of intensive risk factor modification on 
the current stroke risk associated with such lesions.(11) However, several studies are 
planned or ongoing which directly compare carotid intervention plus CMT versus CMT 
alone; these will report in the early 2020s and should clarify the role of carotid intervention 
in such patients.  
The challenge facing clinicians now, when considering how best to treat patients with 
asymptomatic carotid stenosis, is to identify those most at risk of stroke in whom the peri-
procedural risks of carotid intervention are justified. (12-14) Our study demonstrates that in 
ACST-1, patients both with and without prior cerebral infarction benefit from CEA 
regardless of brain imaging findings. However, since prior cerebral infarction is associated 
with a marked increase in stroke risk without intervention, the benefits of surgery are 
greater in this group of patients. Accordingly, a history of cerebral symptoms, or imaging to 
detect prior ‘silent’ cerebral infarction could be helpful when selecting patients for early 
intervention. Nonetheless, such patients should also receive intensive and comprehensive 
risk factor management in an attempt to reduce their overall risk of cardiovascular 
complications and early death.(11,12) 
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Table 1: Symptoms in Group 1 (clinical or radiological evidence of cerebral infarction) 
 
   
N=1331 
n(%) 
   
Ipsilateral silent brain infarct 898 (67.47) 
 amaurosis fugax 67 (5.03) 
 cortical TIA 131 (9.84) 
 stroke 121 (9.09) 
 other / unknown symptoms 114 (8.56) 
   
Contralateral silent brain infarct 466 (35.01) 
 amaurosis fugax 164 (12.32) 
 cortical TIA 348 (26.15) 
 stroke 331 (24.87) 
 other / unknown symptoms  22 (1.65) 
   
 





Table 2: Baseline characteristics of group 1 (symptoms or infarcts) vs group 2 (no 




 Group 2 
(1002) P-value 
n %  n % 
Sex      0.002 
Men 922 (69.3)  632 (63.1)  
Women 409 (30.7)  370 (36.9)  
Age at entry (years)      0.2 
< 65 407 (30.6)  272 (27.2)  
65-74 651 (48.9)  513 (51.2)  
≥ 75 273 (20.5)  217 (21.7)  
mean ± SD 68.5 ± 7.6  68.8 ± 7.6 0.2 
Ipsilateral carotid diameter reduction (% by ultrasound) 0.02 
< 80 569 (42.8)  373 (37.2)  
80-89 355 (26.7)  282 (28.1)  
≥ 90 407 (30.6)  347 (34.6)  
Ispsilateral stenosis 79.0 ± 11.7  80.2 ± 11.0 0.01 
Contralateral stenosis >50% (incl. occlusion) 0.6 
Yes 372 (28.0)  269 (26.9)  
No 959 (72.1)  733 (73.2)  
Diabetes?      1.0 
Yes 267 (20.1)  202 (20.2)  
No 1064 (79.9)  800 (79.8)  
Cardiac disease?      0.9 
Yes 429 (32.2)  320 (31.9)  
No 902 (67.8)  682 (68.1)  
Hyperlipidemia?      0.6 
Yes 1033 (77.6)  787 (78.5)  
No 298 (22.4)  215 (21.5)  
Hypertension?      0.01 
Yes 1138 (85.5)  818 (81.6)  
No 193 (14.5)  184 (18.4)  
Allocated Immediate CEA?      0.3 
Yes 677 (50.9)  486 (48.5)  
No 654 (49.1)  516 (51.5)  
 





Table 3: Number of the first episode of stroke events observed in group 1 and 2 










Territory (regardless of side)  
Carotid 222 (9.5) 138 (10.5) 84 (8.4) 0.03 
VB 23 (1.0) 18 (1.4) 5 (0.5) 0.03 
Unknown 14 (0.6) 11 (0.8) 3 (0.3) 0.06 
Nature     
Ischaemic 166 (7.1) 110 (8.3) 56 (5.6) 0.005 
Haemorrhagic 22 (0.9) 12 (0.9) 10 (1.0) 1.0 
Unknown 71 (3.0) 45 (3.4) 26 (2.6) 0.1 
Lacunar 25 (1.1) 17 (1.3) 8 (0.8) 0.3 
Arterial 147 (6.3) 100 (7.5) 47 (4.7) 0.003 
Cardio-embolic 33 (1.4) 21 (1.6) 12 (1.2) 0.2 
Disabling 77 (3.3) 53 (4.0) 24 (2.4) 0.03 
Non-disabling 109 (4.7) 67 (5.0) 42 (4.2) 0.2 
Any   259 (11.1) 167 (12.5) 92 (9.2) 0.002 
 
* From Cox proportional hazards model, adjusting all other baseline variables listed in table 1 





Table 4: Hazard ratio (HR) of stroke, by baseline characteristics 
 Univariate analysis  Multivariate analysis 
Category HR 95% CI Χ
2
1 p-value  HR 95% CI Χ
2
1 p-value 
Group 1 vs 2 1.50 1.16-1.93 9.7 0.002   1.51 1.17-1.95 9.8 0.002 
Men vs Women 1.10 0.85-1.42 0.5 0.5  1.06 0.82-1.39 0.2 0.6 
Age (per 10 years increase) 1.18 1.00-1.39 3.7 0.05  1.23 1.03-1.46 5.2 0.02 
Ipsilateral stenosis (per 10% ↑) 0.97 0.87-1.07 0.4 0.5  0.94 0.85-1.05 1.3 0.3 
Contralateral stenosis vs no 1.11 0.85-1.46 0.6 0.4  1.14 0.87-1.49 0.8 0.4 
Diabetes vs no 1.60 1.21-2.12 10.9 0.001  1.64 1.23-2.17 11.7 0.0006 
Cardiac disease vs no 1.17 0.90-1.51 1.4 0.2  1.09 0.84-1.41 0.4 0.5 
Hyperlipidemia vs no 0.97 0.72-1.30 0.05 0.8  1.03 0.76-1.39 0.03 0.9 
Hypertension vs no 1.26 0.89-1.79 1.7 0.2  1.16 0.82-1.66 0.7 0.4 
Immediate CEA vs Deferral 0.67 0.52-0.86 10.0 0.002  0.66 0.52-0.85 10.5 0.001 
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Group 2   1002                                680                                   236  





Figure 2  
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